Stay updated on Anti-viral Therapy in Alzheimer's Disease Clinical Trial

Sign up to get notified when there's something new on the Anti-viral Therapy in Alzheimer's Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Anti-viral Therapy in Alzheimer's Disease Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents the dosage of valacyclovir in the study on anti-viral therapy in Alzheimer's disease, where patients will be treated with 4 grams per day of valacyclovir compared to a matching placebo.
    Difference
    0.1%
    Check dated 2024-06-06T14:37:13.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a detailed explanation of eligibility criteria, including examples such as general health condition or prior treatments. Additionally, the inclusion criteria now specify that females must be postmenopausal, defined as 12 consecutive months without menstruation.
    Difference
    41%
    Check dated 2024-05-22T21:00:48.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:35:32.000Z thumbnail image

Stay in the know with updates to Anti-viral Therapy in Alzheimer's Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Anti-viral Therapy in Alzheimer's Disease Clinical Trial page.